Opendata, web and dolomites

DIDO-MS

Commercialization of a first in class multiple sclerosis drug

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "DIDO-MS" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITA DEGLI STUDI DI PERUGIA 

Organization address
address: PIAZZA DELL UNIVERSITA 1
city: PERUGIA
postcode: 6123
website: www.unipg.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-PoC
 Funding Scheme ERC-POC
 Starting year 2018
 Duration (year-month-day) from 2018-02-01   to  2019-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITA DEGLI STUDI DI PERUGIA IT (PERUGIA) coordinator 150˙000.00

Map

 Project objective

Multiple sclerosis (MS) is a chronic and progressive neurodegenerative disease that is currently affecting 2.3 million people worldwide. Incidence rates of MS are significantly higher in Europe and in other regions located within the northern hemisphere. In Europe, the number of patients currently afflicted with MS is estimated to be at 700,000, with incidence rates ranging from 2.3-12.2/100,000 per year. GlobalData assessed the market value for MS treatments in 10 major markets (France, Germany, Italy, Spain, UK, US, Canada, Japan, China and India) in 2014 to be at €16.2 billion and predicts it to rise to approximately €18.82 billion by 2024. This increase is attributed to the projected sales of newly-approved drugs. The main shortcoming of current MS treatments ultimately lies in their lack of efficacy, specifically in that they are unable to prevent progressive neurodegeneration in MS patients. MS poses a significant economic burden on society as the disease affects primarily young people who are in their most economically-productive years. Aside from limited efficacies, current treatment options are also associated with severe side-effects (increased risks of infection, cancer), high costs and inconvenient administration routes (e.g. intravenous, intramuscular, subcutaneous). The aim of DIDO-MS is to assess the commercial viability of a newly identified small molecule as a drug in the treatment of MS.

 Publications

year authors and title journal last update
List of publications.
2019 Marco Gargaro, Carmine Vacca, Serena Massari, Giulia Scalisi, Giorgia Manni, Giada Mondanelli, Emilia M. C. Mazza, Silvio Bicciato, Maria T. Pallotta, Ciriana Orabona, Maria L. Belladonna, Claudia Volpi, Roberta Bianchi, Davide Matino, Alberta Iacono, Eleonora Panfili, Elisa Proietti, Ioana Maria Iamandii, Violetta Cecchetti, Paolo Puccetti, Oriana Tabarrini, Francesca Fallarino, Ursula Grohmann
Engagement of Nuclear Coactivator 7 by 3-Hydroxyanthranilic Acid Enhances Activation of Aryl Hydrocarbon Receptor in Immunoregulatory Dendritic Cells
published pages: , ISSN: 1664-3224, DOI: 10.3389/fimmu.2019.01973
Frontiers in Immunology 10 2020-01-27
2019 Giada Mondanelli, Alberta Iacono, Massimo Allegrucci, Paolo Puccetti, Ursula Grohmann
Immunoregulatory Interplay Between Arginine and Tryptophan Metabolism in Health and Disease
published pages: 1565, ISSN: 1664-3224, DOI: 10.3389/fimmu.2019.01565
Frontiers in Immunology 10 2020-01-27
2019 Claudia Volpi, Ciriana Orabona, Antonio Macchiarulo, Roberta Bianchi, Paolo Puccetti, Ursula Grohmann
Preclinical discovery and development of fingolimod for the treatment of multiple sclerosis
published pages: 1-14, ISSN: 1746-0441, DOI: 10.1080/17460441.2019.1646244
Expert Opinion on Drug Discovery 7 2020-01-27
2019 Giada Mondanelli, Alberta Iacono, Agostinho Carvalho, Ciriana Orabona, Claudia Volpi, Maria T. Pallotta, Davide Matino, Susanna Esposito, Ursula Grohmann
Amino acid metabolism as drug target in autoimmune diseases
published pages: 334-348, ISSN: 1568-9972, DOI: 10.1016/j.autrev.2019.02.004
Autoimmunity Reviews 18/4 2020-01-27

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DIDO-MS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DIDO-MS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

TechChild (2019)

Just because we can, should we? An anthropological perspective on the initiation of technology dependence to sustain a child’s life

Read More  

CHROMREP (2019)

Dissecting the chromatin response to DNA damage in silenced heterochromatin regions

Read More  

DISINTEGRATION (2019)

The Mass Politics of Disintegration

Read More